Galena Biopharma Inc. (GALE: Quote), a biotechnology company focused on developing targeted oncology treatments, announced the issuance of a key patent, originally allowed in March, from the U.S. Patent and Trademark Office covering the use of its product candidate, NeuVax, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH rating of less than 2.0.
NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial that achieved its primary endpoint of disease-free survival, the Food and Drug Administration granted NeuVax a Special Protocol Assessment for its Phase 3 PRESENT study. The Phase 3 trial is ongoing.
Click here to receive FREE breaking news email alerts for Galena Biopharma, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org